Early treatment goals in the bleeding trauma patient have changed based on recent research findings. Trauma patients requiring a massive transfusion protocol have shown a decreased mortality based on a more aggressive and balanced approach to blood product resuscitation. This chapter will review the recent advances in managing the bleeding trauma patient.
INTRODUCTION
Mortality because of severe injury continues to be problematic around the world and is still on the rise [1] . Traumatic injury is the leading cause of death in people aged 1-44 years in the USA and is responsible for more years of life lost than cancer and heart disease combined [2] . Uncontrolled hemorrhage requiring massive transfusion secondary to injury remains one of the leading causes of preventable death. Furthermore, it is now widely accepted that severe coagulopathy because of trauma often adds to the morbidity and mortality of these patients [3] . Much of what we have learned regarding massive transfusion and early goal-directed damage control resuscitation has stemmed from the recent conflicts involving the global war on terrorism [4] . New high-quality civilian studies provide further data to guide therapy. This review will discuss the recent developments involving treatment of the bleeding trauma patient, with a focus on massive transfusion management.
PREHOSPITAL TRANSFUSION
It is widely accepted that severe traumatic blood loss leads to the so-called acute coagulopathy of trauma shock or trauma-induced coagulopathy. Historically, it was believed that acute coagulopathy of trauma shock was a delayed process after acute trauma. We now know that this process begins very soon after severe injury and is diagnosed in up to one-third of severely injured hospital admissions [5, 6] . Furthermore, it is known that a significant number of deaths because of bleeding occur in the first several hours postinjury, as demonstrated in both civilian and military trauma hospitals. As a result, there has been a recent interest in exploring the use of prehospital blood products in bleeding trauma patients. At the Texas Trauma Institute in Houston, liquid plasma and packed red blood cells (RBCs) were placed on board the Life Flight helicopters in 2011 for use in hemorrhagic shock patients. Recent data by Holcomb et al. [7] suggest improved 6-h outcomes with initiation of prehospital blood products. Some data have suggested improved 30-day survival associated with earlier (less than 4 h) in-hospital use of higher plasma to packed RBCs [8, 9] . Currently, there is no prospective data regarding the use of plasma alone as a prehospital resuscitation fluid. Reynolds et al. [10] are among the first groups to create a prospective randomized controlled trial (RCT) protocol for prehospital plasma administration in trauma patients. There are three ongoing prospective randomized studies, and we have just completed a nine center observational trial that enrolled 1019 severely injured patients.
INITIATION OF A MASSIVE TRANSFUSION PROTOCOL
The purpose of a massive transfusion protocol (MTP) is to establish a reproducible institutional system that efficiently delivers blood products from the blood bank to point of care. In the absence of a predefined MTP, delivery of appropriate volumes and ratios of blood components may be haphazard or delayed, increasing the risk of coagulopathy, blood loss, and morbidity [11] . A MTP addresses the organizational issues necessary to respond to massive blood loss in an immediate and sustained manner [12] [13] [14] . It reduces provider variability, facilitates staff communication and compliance, and simplifies the administration of predefined ratios of blood components [15] .
The process of activating a MTP varies with each institution. Whether in the field or upon arrival to the emergency department, a patient's physiology, laboratory, and injury complex can determine the likelihood of substantial bleeding [11, 15] . Scoring systems or algorithms such as the: Trauma-Associated Severe Hemorrhage score, Prince of Wales Hospital/Rainer score, Vandromme score, Assessment of Blood Consumption/Nunez (ABC) score, Schreiber score, and Larsen score have been created with varying degrees of complexity to stratify the risk of substantial bleeding. To highlight one scoring system, the ABC score is a simple accurate nonlaboratory scoring system that is based on four nonweighted parameters: penetrating mechanism, positive focused assessment sonography for trauma, arrival systolic blood pressure of 90 mmHg or less, and arrival heart rate at least 120 bpm. An ABC score of 2 or greater was found to be 75% sensitive and 86% specific for predicting massive transfusion and importantly classified 85% of bleeding patients [16] . Utilizing a scoring system to guide the activation of the MTP removes provider experience and standardizes the assessment to more accurately identify those patients at risk of substantial bleeding. Pommerening et al. [17 & ] 2015 Prospective, Observational, Multicenter, Major Trauma Transfusion study demonstrated that utilizing a scoring system was superior to physician gestalt in predicting which patients require MTP activation.
Once a clinical diagnosis of substantial bleeding is made, the attending physician activates the blood bank MTP, which triggers the release of a predefined ratio of blood components (i.e., type O negative uncrossed packed red blood cell, AB-negative plasma, and single donor platelets). Rapid release of these products is possible by maintaining several thawed universal donor (AB) plasma units (4-6 units) at all times [15] . A type and screen is immediately sent to the blood bank with basic information including: the ordering physician, patient's name or alias, sex, medical record number, and patient's location. The blood is prepared and delivered in a fixed ratio until the blood bank is notified to stop. Data suggest that MTPs shorten the initial time for first product delivery and improves efficiency of delivery for future cycles of blood products [15,17 & ]. Riskin [18], found survivor benefit (reduction from 45 to 19% morality P ¼ 0.02) with reduced time to first product in MTP patients. Sustained delivery of blood products minimizes time to delivery, limits the infusion of crystalloid and artificial colloids, and improved patient outcome.
RECENT MASSIVE TRANSFUSION UPDATES
administration in bleeding trauma patients. In 2008, Holcomb et al. [9] demonstrated a benefit to transfusing higher plasma and platelet ratios in massively transfused trauma patients, thus warranting a closer look at a more balanced resuscitation protocol. The recent findings of the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) support a balanced approach to initial massive transfusion. The study by Holcomb and colleagues compared two different ratios of fresh frozen plasma (FFP) : platelet concentrate : RBC (1 : 1 : 1 vs. 1 : 1 : 2). A total of 680 patients meeting criteria for highestlevel trauma activation were randomized and included in the study, admitted to 12 North American Level 1 trauma centers. Primary end points of the PROPPR study were mortality at 24 h and 30 days to address safety concerns in the higher plasma group. No significant difference in mortality was observed at 24 h or 30 days. The 1 : 1 : 1 group demonstrated significantly less exsanguination and overall higher survival at 3 h compared with the 1 : 1 : 2 arm. In addition, there was no increase in acute respiratory distress syndrome or transfusion-related complications. The survival benefit in the 1 : 1 : 1 group was a 4% reduction in mortality in the randomized patients [19 && ]. Hence, in the early management of the severely bleeding trauma patient, there is now adequate support for a more balanced resuscitation protocol utilizing a 1 : 1 : 1 approach.
In light of these recent studies, there has been controversy concerning blood product wastage utilizing a balanced resuscitation protocol. In support of an aggressive, balanced approach to massive transfusion, most data now suggest that this method of transfusion actually limits the overall amount of product used while enhancing survival [20, 21] . Furthermore, the question of when to stop a MTP and switch to a more goal-directed therapy has emerged. It is of paramount importance to have clear and concise clinical goals to guide stopping a MTP [22 & ]. Recently, Johansson and colleagues [23 && ] describe the approach of starting with ratios and then as bleeding slows and the rate of transfusion decreases, switching to thromboelastography (TEG)-guided (goal-directed) transfusion. Additional evidence of support for this relatively new concept of balanced trauma resuscitation has been shown in other patients such as liver transplants, vascular, and cancer surgeries [24, 25] .
CONCEPT OF DAMAGE CONTROL RESUSCITATION/DAMAGE CONTROL SURGERY AND HEMOSTATIC RESUSCITATION
Damage control surgery (DCS), limits extensive procedures on unstable patients with the goal of stabilizing potentially fatal problems and minimizing contamination and hemorrhage [26] . Initial surgical procedures provide only interventions necessary to control bleeding and contamination and focuses on re-establishing a survivable physiologic state. Reoperation to restore anatomy and achieve definitive repair is then staged after successful resuscitation is achieved.
Hemostatic resuscitation is a core component of damage control resuscitation (DCR) used to describe a unified transfusion approach to severe hemorrhagic shock in the trauma patient [4] . This structured intervention begins immediately after the field assessment and is continued through the odds ratio (OR) and into the postsurgical intensive care unit. Hemostatic resuscitation is intended to minimize dilutional coagulopathy by replacing lost blood with plasma and platelet-containing products [27] .
Both DCR and DCS are utilized in a minority of everyday patients, but both are used in the patients with increased risk of hemorrhagic death. Cotton et al. [28] published a large series investigating the efficacy of DCR concepts in DCS patients in the civilian setting. Applying all three tenets, this study identified a reduction in crystalloid and overall blood product administration and inflammatory consequences of shock. DCR was associated with a 2.5-fold increased in 30-day survival [28] .
LABORATORY TESTS AND UTILIZATION IN MASSIVELY BLEEDING TRAUMA PATIENTS
In light of the explosion of recent data regarding the timing and quantities of blood product usage in the bleeding trauma patient, there has been a renewed interest in laboratory-guided resuscitation principles. Traditionally, the bleeding trauma patient would have a 'trauma panel' of labs sent on arrival to the trauma center that included a complete blood count, chemistry panel, an arterial blood gas analysis, and coagulation profile (prothrombin time/partial thromboplastin time). Over the last decade or so, we now know that this 'trauma panel' does little to guide the astute clinician in the initial resuscitation phase of massive transfusion. Recent work in the hemostatic analysis of bleeding patients has demonstrated a renewed interest in viscoelastical hemostatic assays. These include both TEG and thromboelastometry. These viscoelastic tests can identify deficits in clotting factors, initiation of clot, clot strength, and excessive clot breakdown [29] . This allows the clinician a real time 'dynamic' view of the patient's ability to make clot and retain it during resuscitation. As a result, goal-directed transfusion therapy can be implemented throughout the entire resuscitation phase of patient care. A plethora of clinical studies have supported the use of these viscoelastic assays in the management of bleeding in liver, cardiac, and trauma surgery cases. These studies bolster the superiority of viscoelastic assays to monitor and guide hemostatic resuscitation in comparison to traditional coagulation panels. This results in a reduction in transfusion requirements, surgical 're-do' procedures, and overall mortality [30] Of importance, it should be noted that standard viscoelastic tests are unable to measure pharmacological platelet inhibitors such as aspirin or clopidogrel. Hence, the TEG Platelet Mapping Assay (Haemonetics Corp, Braintree, Massachusetts, USA) or the whole blood platelet impedance aggregometry assay Multiplate (Roche, Basel, Switzerland) can be utilized to identify potential pharmacological platelet inhibition. A further limitation is the lack of measurement of endothelial function by any current coagulation test.
In Houston, the rapid TEG approach is utilized, which uses tissue factor in addition to kaolin to speed the initiation of the clotting process and thus obtain results more expeditiously. Holcomb and colleagues studied this approach in 1974 consecutive trauma patients on arrival to our institution. They found that the rapid TEG was clinically superior to alternative coagulation tests in identifying patients requiring immediate blood product transfusion as well as identification of fibrinolysis [31] . Furthermore, it is clinically important to rapidly identify excessive clot fibrinolysis using the rapid TEG Ly30. Any Ly30 at least 3% warrants tranexamic acid therapy if the patient is within 3 h of injury.
In addition to viscoelastic assays during massive transfusion, it is our current practice to analyze arterial blood gases to follow hemoglobin, lactate, and base deficit levels throughout resuscitation. This is a common approach and still considered the standard of care with respect to guiding resuscitation goals. Standard arterial blood gas analysis allows the clinician to determine if and when resuscitation is beneficial and to what end point. Typically, massive transfusion is stopped when blood loss source control is achieved/hemostasis restored, transfusion rates are decreasing, hemodynamic stability is observed, continuous pressor requirements are decreasing or absent, urine output is adequate, and results of viscoelastic assays/blood gas analyses are reassuring. Thus, a combination of balanced transfusion, laboratory values, hemodynamics, urine output, and goal-driven therapy are currently the mainstay of massive trauma resuscitation.
BLEEDING ADJUNCTS (TRANEXAMIC ACID, PROTHROMBIN COMPLEX CONCENTRATES, RECOMBINANT ACTIVATED FACTOR VII, ETC)

Adjunct therapy; tranexamic acid
The Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage (CRASH)-2 study, a large multicentered RCT, examined the effect of tranexamic acid (TXA) on mortality and transfusion requirements in 20 000 adult patients with traumatic injury and hemorrhagic shock [32] . Allcause mortality and mortality from bleeding were improved following TXA administration [RR ¼ 0.91; 95% confidence interval (CI) 0.85-0.97 and (RR ¼ 0.85; 95% CI 0.76-0.96), respectively] [32] . Military Application of TXA in Trauma Emergency Resuscitation (MATTERs) study was a retrospective observational study comparing TXA with no TXA in combat casualty patients (n ¼ 896; 293 TXA) treated in southern Afghanistan. In the MATTERs trial similar benefit was present in the combat injured as was observed in the CRASH-2 trial. Despite being more severely injured, the TXA group had lower unadjusted mortality than the non-TXA group (17.4% vs. 23.9%, respectively; P ¼ .03), was independently associated with survival [odds ratio (OR) ¼ 7.228; 95% CI, 3.016-17.322] and less coagulopathy (P ¼ 0.003) [33] . However, rates of pulmonary embolism and deep venous thrombosis were significantly higher with TXA administration (2.7 and 2.4%) vs. without (0.3 and 0.2%) [33] . In a recent analysis by Cole et al. [34] , TXA was independently associated with a reduction in multiorgan failure (OR ¼ 0.27, CI 0.10-0.73, P ¼ 0.01) and was protective for adjusted all-cause mortality (OR ¼ 0.16 CI 0.03-0.86, P ¼ 0.03) in shocked patients.
The CRASH-2 study provoked international debate, about its applicability and predictability beyond the context of its study sites. Criticism of the study included lack of measurement of severity of injury, a large patient enrollment from lowincome countries with limited blood supply or access to advanced interventions, and its application in traumatic brain injury. Additionally, only 50% of enrolled patients received any blood products. Less than 2% of the CRASH-2 study cohort was treated in countries with advanced trauma systems. evaluating the risk reduction and mortality of TXA within an advanced medical system targeting 1184 severely injured patients at high risk of traumatic coagulopathy. The Crash-3 trial is an international, multicenter, pragmatic, randomized, double-blind, placebo-controlled trial designed to quantify the effects of the early TXA vs. placebo on death and disability in adult traumatic brain injury (TBI) patients (n ¼ 10 000). The National Institutes of Health and Department of Defense are sponsoring and have enrolled 170 patients into a trial of TBI patients in North America. The hope is these large multicenter trials will strengthen our understanding of TXA in the trauma patient.
Fibrinogen concentrate
Early reports from nonrandomized studies of fibrinogen concentrate in traumatic hemorrhage have been promising. Schochl et al. [35] described use of fibrinogen concentrates with decreased RBC transfusion requirements (29 vs. 3%, P < 0.001) and platelet utilization (91 of vs. 56%). Frequency of multiorgan failure was also significantly decreased in patients exclusively treated with coagulation factor concentrates [35] . Similarly, Aubron et al.'s [36] recent review of fibrinogen concentrates was found to be safe, decreased blood product requirements, reduced the potential for hemorrhagic shock and multi-organ failure, in the hypofibrinogenemia trauma patients. Currently, RCTs looking at the superiority of cryoprecipitate vs. fibrinogen concentrates or the importance of the timing of administration of fibrinogen concentrates in the trauma patient is lacking. Future prospective RCTs with sufficient power are necessary to investigate the benefit and safety of fibrinogen concentrate in the substantial bleeding patient [35, 36] .
Prothrombin complex concentrate
Prothrombin complex concentrate (PCC) is a concentrated vitamin K-dependent factor derived from large donor-pooled plasma. PCCs contain either three or four coagulation factors, including factors II, IX, and X, and in the four factor formulation, factor VII. Additionally, some PCC formulations also have low doses of coagulation inhibitors such as protein C and S and heparin. PCCs do not require crossmatching, can be rapidly administered, and have minimal risk of infection, transfusion-related circulatory overload, or acute lung injury [37] . Originally approved for use in the treatment of hemophilia B, PCCs are now the first-line reversal recommendation and standard of care for vitamin K antagonist both abroad and in the USA [37] .
The benefit of PCCs in trauma is intriguing in DCR of the substantial bleeding patient. PCCs provide rapid factor replacement and may be an effective alternative to FFP [38] . In Grottke et al.'s [39 & ] review of retrospective and observational trials, PCCs were found to decrease mortality, blood loss, and total transfusion requirements. However, the lack of prospective, RCTs prevents evidence-based recommendations for PCC use in perioperative bleeding. Additionally, PCCs currently are 10 times more expensive than FFP. High-quality studies are needed to define efficacy, safety, cost-effectiveness, optimum dosing, timing, and optimal PCC composition for use in the trauma population [39 & ].
rFVIIa Two RCTs have been published evaluating the effectiveness of recombinant activated factor VII (rFVIIa) in trauma patient [40, 41] . Both studies reported a reduction in transfused packed red blood cell following rFVIIa administration in blunt trauma although an improvement in mortality was not observed [40, 41] . No increased complications were seen in the trauma population. A Cochrane review does not support rFVIIa as standard treatment for traumatic bleeding [42] .
CONCLUSION
Based on the data presented above the National Institute for Health & Care Excellence policy and Trauma Quality Improvement Program guidelines support balanced ratio driven transfusion approaches in patients with massive blood loss. Balanced blood product resuscitation protocols and goal-directed therapy are emerging as the mainstays of treatment strategies in the massively bleeding trauma patient population. In addition, hypotensive and hemostatic resuscitation approaches are also equally important to the overall success in resuscitation of acutely injured patients. Recent literature now supports the early use of a 1 : 1 : 1 blood product transfusion protocol to restore lost circulating volume, improve oxygen carrying capacity, replace diluted platelets, and replenish clotting factors. Further studies are needed to determine whether prehospital initiation of blood products and point of care testing will improve outcomes of trauma resuscitation.
